Emmes
Emmes is a global full-service clinical research organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation. With over 47 years of experience, Emmes has conducted more than 2,150 clinical trials across various therapeutic areas, including vaccines and infectious diseases, ophthalmology, neurology, rare diseases, and cell & gene therapies. The company leverages technology and AI to enhance clinical research efficiency and quality, aiming to improve patient outcomes and accelerate the delivery of new treatments.
Industries
Nr. of Employees
Very Large (1000+)
Emmes
401 N. Washington Street, Suite 700, Rockville, MARYLAND 20850, UNITED STATES
Products
AI agent for data management
An AI assistant that automates study build tasks, discrepancy detection, query review, protocol compliance checks, data quality monitoring, and SDTM conversion pipelines to accelerate data readiness.
AI agent for biostatistics and analysis
An AI-driven tool that automates TFL shell generation, assembles interim and DSMB packages, standardizes outputs, and prepares analysis-ready deliverables.
AI document authoring copilot
AI-assisted document generation for clinical study documents (protocols, reports, regulatory submissions) trained with domain expert oversight to produce structured, regulatory-aligned drafts.
Unified eClinical platform
A fully integrated cloud-based platform combining EDC, IRT/RTSM, ePRO/eCOA, eConsent, DCT enablement, specimen tracking, operational dashboards and reporting.
Clinical data analytics pipelines
Automated analytics workflows for large and complex biological datasets, including real-world data and omics, to generate disease and treatment insights.
AI agent for data management
An AI assistant that automates study build tasks, discrepancy detection, query review, protocol compliance checks, data quality monitoring, and SDTM conversion pipelines to accelerate data readiness.
AI agent for biostatistics and analysis
An AI-driven tool that automates TFL shell generation, assembles interim and DSMB packages, standardizes outputs, and prepares analysis-ready deliverables.
AI document authoring copilot
AI-assisted document generation for clinical study documents (protocols, reports, regulatory submissions) trained with domain expert oversight to produce structured, regulatory-aligned drafts.
Unified eClinical platform
A fully integrated cloud-based platform combining EDC, IRT/RTSM, ePRO/eCOA, eConsent, DCT enablement, specimen tracking, operational dashboards and reporting.
Clinical data analytics pipelines
Automated analytics workflows for large and complex biological datasets, including real-world data and omics, to generate disease and treatment insights.
Expertise Areas
- Clinical trial management
- Clinical data management
- Biostatistics and adaptive trial design
- Regulatory affairs and submissions
Key Technologies
- Electronic data capture (EDC)
- IRT/RTSM (interactive response technology)
- eCOA / ePRO
- eConsent
Key People
News & Updates
Emmes awarded multi-task, IDIQ contract with $50M ceiling, to support NIDA’s clinical trials network
Emmes has been awarded a contract to support the National Institute on Drug Abuse's Clinical Trials Network, continuing its long-standing partnership with the NIH.
The acquisition of VaxTRIALS enhances Emmes' capabilities in vaccine research across Latin America.
Emmes announced the creation of the Emmes Group, which will include a new business unit, Veridix AI, focused on embedding technology and AI in clinical operations.
Emmes Endpoint Solutions has submitted a qualification plan to the FDA for a novel video assessment tool for Duchenne muscular dystrophy.
98% Client retention rate
Emmes has maintained a 98% client retention rate, showcasing its commitment to client satisfaction and service quality.
2,150+ Clinical trials conducted
Emmes has successfully conducted over 2,150 clinical trials in more than 90 countries, demonstrating its global reach and expertise.
Emmes awarded multi-task, IDIQ contract with $50M ceiling, to support NIDA’s clinical trials network
Emmes has been awarded a contract to support the National Institute on Drug Abuse's Clinical Trials Network, continuing its long-standing partnership with the NIH.
The acquisition of VaxTRIALS enhances Emmes' capabilities in vaccine research across Latin America.
Emmes announced the creation of the Emmes Group, which will include a new business unit, Veridix AI, focused on embedding technology and AI in clinical operations.
Emmes Endpoint Solutions has submitted a qualification plan to the FDA for a novel video assessment tool for Duchenne muscular dystrophy.
98% Client retention rate
Emmes has maintained a 98% client retention rate, showcasing its commitment to client satisfaction and service quality.
2,150+ Clinical trials conducted
Emmes has successfully conducted over 2,150 clinical trials in more than 90 countries, demonstrating its global reach and expertise.